SLGL Sol-Gel Technologies Ltd.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1684693 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY68.0%
TTM net income YoY42.1%
TTM EPS YoY42.2%
Revenue 3-yr CAGR70.9%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-38.9%
Net margin-31.6%
FCF margin1.4%
EBITDA margin-38.3%
Returns
ROE-23.7%
ROA-18.6%
ROIC (approx.)-56.3%
Asset turnover0.59x
Leverage & solvency
Liabilities / assets23.8%
Debt / equity0.00x
Current ratio4.37x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.05x
Accruals ratio-19.6%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $19.39M | $11.54M |
| R&D expense | $22.80M | $17.80M |
| SG&A expense | $4.18M | $5.75M |
| Operating income | -$7.54M | -$12.01M |
| Income tax | $0 | $0 |
| Net income | -$6.13M | -$10.58M |
| EBITDA | -$7.43M | -$11.78M |
| EPS (basic) | -2.19 | -3.79 |
| EPS (diluted) | -2.19 | -3.79 |
| Weighted avg. shares (diluted) | 2.79M | 2.79M |
| Balance sheet | ||
| Cash & equivalents | $11.03M | $19.49M |
| Short-term investments | $12.97M | $4.42M |
| Receivables | $1.97M | $3.60M |
| Current assets | $26.97M | $31.30M |
| PP&E, net | $140,000 | $202,000 |
| Total assets | $29.92M | $35.85M |
| Current liabilities | $6.17M | $5.29M |
| Total liabilities | $7.11M | $7.00M |
| Shareholders' equity | $22.81M | $28.85M |
| Shares outstanding | 2.79M | 2.79M |
| Cash flow statement | ||
| Operating cash flow | $322,000 | -$13.89M |
| Capital expenditure | $47,000 | $2,000 |
| Free cash flow | $275,000 | -$13.89M |
| Investing cash flow | -$8.58M | $26.69M |
| Financing cash flow | $6,000 | $0 |
| Depreciation & amortization | $109,000 | $233,000 |
| Stock-based compensation | $82,000 | $786,000 |
Free plan shows the latest 2 periods; Pro shows all 11 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.